Adapt Pharma submits NDA to FDA for Narcan nasal spray
Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Within 60 days of the submission date, the FDA will determine whether it will accept the
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
Zerbaxa for injection (1.5g) is an antibacterial combination product for intravenous infusion consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam sodium. The positive
The recalled lots are as follows:Lot # Exp. Date Vial Size NDC# individual vials NDC# carton of 5 vials31317857B 8/2015 100 mL 0703-3019-11 0703-3019-1231317859B 12/2015 100 mL 0703-3019-11